ArticleCureus2025
Predictors of Disease Progression in Idiopathic Pulmonary Fibrosis Under Antifibrotic Therapy: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tidal Volume in Idiopathic Pulmonary Fibrosis: Restriction Severity and Prognostic Information beyond Forced Vital Capacity.Respiration; international review of thoracic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive fibrosing lung disease with a low median survival of three to five years. Antifibrotic agents, pirfenidone and nintedanib, slow but do not reverse disease progression, and treatment response varies. Identifying baseline predictors of progression may help personalize care.
methodsWe retrospectively analyzed consecutive IPF patients treated at Okinawa Chubu Hospital between 2012 and 2020. Eligible patients received antifibrotics for ≥3 months and had baseline and follow-up pulmonary function tests (PFTs). Clinical, laboratory, PFT, and high-resolution computed tomography (HRCT) data were collected. Disease progression within one year was defined as ≥2 of: worsening symptoms, ≥5% decline in forced vital capacity (FVC), or radiologic progression. Predictors were evaluated using exact logistic regression; survival was assessed with Kaplan-Meier analysis.
resultsForty-seven patients (mean age 73.3 years, 32 men) were included; 63.8% were ever-smokers. Mean baseline FVC was 1.93 L, %FVC 67.6%, % peak expiratory flow (PEF) 75.0%, %total leucocyte count (TLC) 72.4%, %diffusing capacity of the lungs for carbon monoxide (
conclusionsLower %PEF and %TLC may predict poorer response to antifibrotics in IPF. These readily available PFT indices could serve as practical markers for risk stratification and early intervention. Prospective, multicenter studies are warranted to confirm predictive value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.